Patents Assigned to The University of Texas Systems
  • TARGETING ALPHA3BETA1 INTEGRIN FOR TREATMENT OF CANCER AND OTHER DISEASES
    Publication number: 20230139944
    Abstract: Provided herein, in some aspects, are agents, such as antibodies, chimeric antigen receptors, or RNA interference molecules that target the interaction between ?3?1 integrin and ?1 homotrimeric type I collagen. Aspects are directed to methods of treating cancer and fibroids comprising administering to a patient in need thereof an effective amount of an agent that disrupts the interaction between ?3?1 integrin and ?1 homotrimeric type I collagen. The methods can further include administering an effective amount of chemotherapy or immunotherapy to said patient.
    Type: Application
    Filed: June 17, 2020
    Publication date: May 4, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventor: Raghu KALLURI
  • Systems and methods for locating an inserted catheter tip
    Patent number: 11638611
    Abstract: In one embodiment, a system for locating a tip of a catheter that has been inserted into a patient includes an implantable catheter having a distal tip, a pulsed light source that is co-located with the distal tip of the implantable catheter, the pulsed light source being configured to emit pulses of light into surrounding patient tissue, an optoacoustic sensor configured to be applied so a skin surface of the patient at a position proximate to the pulsed light source and to sense optoacoustic waves generated when the pulses of light are absorbed by the surrounding patient tissue, and an optoacoustic console configured to receive optoacoustic wave signals from the optoacoustic sensor and to display an indication of the optoacoustic wave signals to a medical professional to provide an indication of the location of the pulsed light source and, therefore, the distal tip of the implantable catheter.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: May 2, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Rovnat Babazade, Yuriy Petrov, Irene Petrov, Rinat O. Esenaliev
  • Softening nerve cuff electrodes
    Patent number: 11638816
    Abstract: A nerve cuff electrode device comprising a cuff body having a smart memory polymer layer with a rigid configuration at room temperature and a softened configuration at about 37° C. The smart memory polymer layer has a trained curved region with a radius of curvature of about 3000 microns or less. A plurality of thin film electrodes located on the smart memory polymer layer. The thin film electrodes include discrete titanium nitride electrode sites that are located in the trained curved region. An exposed surface of each of the discrete titanium nitride electrode sites has a charge injection capacity of about 0.1 mC/cm2 or greater. Methods or manufacturing and using the device are also disclosed.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: May 2, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Romil Modi, Walter E. Voit, Mario Romero-Ortega
  • METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF
    Publication number: 20230130134
    Abstract: The present invention relates to methods of treating and preventing viral diseases and infections comprising the administration of hexoses and analogs and their prodrugs thereof that inhibit glycolysis and/or glycosylation.
    Type: Application
    Filed: March 16, 2021
    Publication date: April 27, 2023
    Applicants: Board of Regents, The University of Texas System, Moleculin Biotech, Inc.
    Inventors: Waldemar PRIEBE, Izabela FOKT, Rafal ZIELINSKI, Stanislaw SKORA, Donald PICKER, Walter KLEMP
  • MONOCLONAL ANTIBODIES TARGETING HSP70 AND THERAPEUTIC USES THEREOF
    Publication number: 20230128075
    Abstract: Provided herein are agents, such as antibodies and chimeric antigen receptors, that target HSP70. Methods of treating cancer are provided, comprising administering to a patient in need thereof an effective amount of an HSP70-targeting agent. The HSP70-specific antibody may enhance uptake of HSP70 by antigen presenting cells.
    Type: Application
    Filed: March 26, 2021
    Publication date: April 27, 2023
    Applicants: Board of Regents, The University of Texas System, Asylia Therapeutics
    Inventors: Robert Z. ORLOWSKI, Richard J. JONES, Laura C. BOVER, Jeno GYURIS, John MILLER, James Bernard McCLORY, Darragh MAC CANN, William M. WINSTON, SR.
  • USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS
    Publication number: 20230121116
    Abstract: Provided herein are methods of selecting cancer patients for treatment with quinazoline-based tyrosine kinase inhibitors, either alone or in combination with anti-HER2/HER3 antibodies, as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with quinazoline-based tyrosine kinase inhibitors alone or in combination with anti-HER2/HER3 antibodies.
    Type: Application
    Filed: January 29, 2021
    Publication date: April 20, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: John HEYMACH, Jacqulyne ROBICHAUX
  • OX2R Compounds
    Publication number: 20230122024
    Abstract: Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.
    Type: Application
    Filed: October 21, 2022
    Publication date: April 20, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jef De Brabander, Daniel Rosenbaum, Qiren Liang, Wentian Wang
  • Simulation and patient-specific scale tissue modelling of the growth of prostate cancer
    Patent number: 11631502
    Abstract: In an embodiment, a simulation of the evolution of a tumor in a prostate gland of a subject is based at least on a coupled system of reaction-diffusion equations and a patient-specific geometric model of the prostate gland of the subject. The use of reaction-diffusion equations and a patient-specific geometric model provides a tumor model that predicts the expected progression of prostate cancer in the subject. The tumor model may be used to devise a customized treatment for the subject.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: April 18, 2023
    Assignees: Board of Regents, The University of Texas System, University of A Coruna
    Inventors: Thomas J. R. Hughes, Hector Gomez, Guillermo Lorenzo
  • SARS-COV-2 VACCINE
    Publication number: 20230113170
    Abstract: SARS-CoV-2 S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the SARS-CoV-2 S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to SARS-CoV-2 S in a subject, for example, an immune response that inhibits SARS-CoV-2 infection in the subject.
    Type: Application
    Filed: February 11, 2021
    Publication date: April 13, 2023
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human, Board of Regents, The University of Texas System, Trustees of Dartmouth College
    Inventors: Barney Graham, Kizzmekia Corbett, Olubukola Abiona, Geoffrey Hutchinson, Jason McLellan, Daniel Wrapp, Nianshuang Wang
  • USE OF EGFR/HER2 TYROSINE KINASE INHIBITORS AND/OR HER2/HER3 ANTIBODIES FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS
    Publication number: 20230112470
    Abstract: Provided herein are methods of selecting cancer patients for treatment with a covalent EGFR/HER2 TKI, a HER2/HER3 targeting antibody, or a combination of a covalent EGFR/HER2 TKI and a HER2/HER3 targeting antibody as well as methods of treating cancer patients so selected. Cancer patients are selected for treatment if their cancer has an NRG1 fusion. Selected patients are then treated with a covalent EGFR/HER2 TKI, a HER2/HER3 targeting antibody, or a combination of a covalent EGFR/HER2 TKI and a HER2/HER3 targeting antibody.
    Type: Application
    Filed: January 29, 2021
    Publication date: April 13, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: John HEYMACH, Jacqulyne ROBICHAUX
  • Microneedle array electroporation system for cell transfection
    Patent number: 11624050
    Abstract: Disclosed is the design, fabrication, and characterization of a novel system comprising a parallel set of nanopore microneedles (NPMs) for cell transfection through controlled nanoelectroporation (NEP) and electrophoretic insertion of genetic materials.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: April 11, 2023
    Assignee: Board of Regents, The University of Texas System
    Inventors: Lingqian Chang, R. Lyle Hood, Forhad Akhter
  • System and method for roll-to-roll film tensioning for reduced separation force during bottom-up stereolithography
    Patent number: 11623396
    Abstract: The present disclosure relates to a tensioning system for use in a stereolithography manufacturing application. The system may have a build plate for supporting a three dimensional part being formed using a photo responsive resin, a base plate and a release element extending over the base plate. The release element is configured to receive a quantity of photo responsive resin for forming a new material layer of the three dimensional part. A pair of tensioning components are secured to opposite ends of the release element, and apply a controlled tension force to the release element during peeling of the release element to reduce a separation force required to separate the release element from the new material layer after the new material layer is cured.
    Type: Grant
    Filed: September 22, 2020
    Date of Patent: April 11, 2023
    Assignees: Lawrence Livermore National Security, LLC, Board of Regents, The University of Texas System
    Inventors: Eric B. Duoss, James Oakdale, Nicholas Anthony Rodriguez, Hongtao Song, Richard Crawford, Carolyn Seepersad, Morgan Chen
  • METHODS FOR EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES AND USE THEREOF
    Publication number: 20230106973
    Abstract: Provided herein are methods for the activation and expansion of genetically-modified Tcells, such as tumor infiltrating lymphocytes. In some cases, cells of the embodiments can be used for the therapeutic treatment of human diseases, such as cancer.
    Type: Application
    Filed: February 16, 2021
    Publication date: April 6, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Marie-Andrée FORGET, Chantale BERNATCHEZ, Cara HAYMAKER, Michael A. CURRAN, Patrick HWU, Cassian YEE
  • CHIMERIC SCAVENGER RECEPTORS TARGETED TO PHOSPHORYLATED TAU (PTAU) AND USES THEREOF
    Publication number: 20230109553
    Abstract: Provided herein are chimeric scavenger receptor where the endogenous binding region is replaced with an antigen-specific binding region to redirect the specificity of the receptor. Also provided are immune cells, such as, for example, monocytes, that are engineered to express the chimeric scavenger receptor. Also provided are methods of treating patients, such as, for example, Alzheimer's patients, by administering the engineered monocytes.
    Type: Application
    Filed: January 15, 2021
    Publication date: April 6, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Michael A. CURRAN, Chao-Hsien CHEN
  • Composite positive electrode active material for lithium secondary battery, method of preparing the same, positive electrode for lithium secondary battery including the same, and lithium secondary battery including the positive electrode
    Patent number: 11621419
    Abstract: A method of preparing a composite positive electrode active material for a lithium secondary battery includes surface-treating a nickel-based active material using carbon dioxide to form a lithium carbonate layer on the surface of the nickel-based active material, mixing the nickel-based active material having the lithium carbonate layer on the surface thereof with a metal precursor including at least one metal selected from cobalt (Co), aluminum (Al), magnesium (Mg), and gallium (Ga) to prepare a mixture, and heat-treating the mixture. A composite positive electrode active material for a lithium secondary battery may be obtained according to the method; and used in a positive electrode for a lithium secondary battery.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: April 4, 2023
    Assignees: Samsung SDI Co., Ltd., Board of Regents, The University of Texas System
    Inventors: Arumugam Manthiram, Youngjin Kim, Byongyong Yu
  • IMPROVED SPINAL IMPLANT
    Publication number: 20230094575
    Abstract: This disclosure describes spinal implants with anchoring elements including an aperture for delivery of injectable materials. In one aspect, a spinal implant includes a body defining one or more injection ports and one or more channels, the one or more injection ports configured to receive flowable material and to provide the flowable material to the one or more channels; and one or more anchoring elements protruding from a surface of the body, the one or more anchoring elements each defining an aperture coupled to the one or more channels and configured to receive the flowable material from the one or more channels and to provide/output the flowable material from the aperture.
    Type: Application
    Filed: March 15, 2021
    Publication date: March 30, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Justin Earl BIRD, Nicolas M. CORDARO, Jeffrey M. BRITTAN
  • NOVEL BLOCK COPOLYMER AND MICELLE COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230085899
    Abstract: Provided herein are block copolymers comprising a hydrophilic polymer segment and a hydrophobic polymer segment, wherein the hydrophilic polymer segment comprises a polymer selected from the group consisting of: poly(ethylene oxide) (PEO), poly(methacrylate phosphatidyl choline) (MPC), and polyvinylpyrrolidone (PVP), wherein the hydrophobic polymer segment comprises wherein R? is —H or —CH3, wherein R is —NR1R2, wherein R1 and R2 are alkyl groups, wherein R1 and R2 are the same or different, wherein R1 and R2 together have from 5 to 16 carbons, wherein R1 and R2 may optionally join to form a ring, wherein n is 1 to about 10, and wherein x is about 20 to about 200 in total. Also provided are pH-sensitive micelle compositions for therapeutic and diagnostic applications.
    Type: Application
    Filed: July 1, 2022
    Publication date: March 23, 2023
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Jinming GAO, David BOOTHMAN, Kejin ZHOU, Xiaonan HUANG, Yiguang WANG
  • HUMAN 4-1BB AGONIST ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230092390
    Abstract: Isolated or recombinant monoclonal antibodies that bind to 4-1BB are provided. In son cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
    Type: Application
    Filed: February 17, 2021
    Publication date: March 23, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Michael A. CURRAN, Renee CHIN, Marie-Andrée FORGET, Chantale BERNATCHEZ
  • METHODS FOR RAPID CLONING AND EXPRESSION OF HLA CLASS I CELLS
    Publication number: 20230079539
    Abstract: The present disclosure provides methods of generating HLA class-I null cells that can be used for expression of exogenous HLA genes and presentation of antigens, such tumor neoantigens. Method for using HLA class-I null cells from selecting, stimulating and propagating immune effector cells are also provided.
    Type: Application
    Filed: February 10, 2021
    Publication date: March 16, 2023
    Applicant: Board of Regents, The University of Texas System
    Inventors: Hiroki TORIKAI, Shan ZONG
  • METHODS FOR THE ASSESSMENT OF RISK AND TREATMENTS FOR LIVER CANCERS AND LETHAL LIVER DISEASE COMPLICATIONS
    Publication number: 20230073981
    Abstract: Disclosures herein are directed to methods and compositions for predicting high- and low-risk liver disease in patients. Based on the results achieved from the methods and compositions disclosed herein, liver disease patients can be classified into a prognostic risk group, which enables early diagnosis and prevention of HCC and other lethal complications. Methods and compositions disclosed herein substantially improve the poor prognosis of subjects having or at risk for one or more liver diseases.
    Type: Application
    Filed: August 26, 2022
    Publication date: March 9, 2023
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Yujin Hoshida, Naoto Fujiwara, Amit G. Singal, Thomas F. Baumert